HK1094036A1 - Evaluation of adjuvanted vaccines - Google Patents

Evaluation of adjuvanted vaccines

Info

Publication number
HK1094036A1
HK1094036A1 HK07100314.2A HK07100314A HK1094036A1 HK 1094036 A1 HK1094036 A1 HK 1094036A1 HK 07100314 A HK07100314 A HK 07100314A HK 1094036 A1 HK1094036 A1 HK 1094036A1
Authority
HK
Hong Kong
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Application number
HK07100314.2A
Other languages
English (en)
Inventor
Peter Adler Wurtzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1094036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of HK1094036A1 publication Critical patent/HK1094036A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK07100314.2A 2003-08-05 2007-01-10 Evaluation of adjuvanted vaccines HK1094036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05
PCT/DK2004/000514 WO2005022157A1 (en) 2003-08-05 2004-07-28 Evaluation of adjuvanted vaccines

Publications (1)

Publication Number Publication Date
HK1094036A1 true HK1094036A1 (en) 2007-03-16

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100314.2A HK1094036A1 (en) 2003-08-05 2007-01-10 Evaluation of adjuvanted vaccines

Country Status (13)

Country Link
EP (1) EP1649287B1 (xx)
KR (1) KR101132439B1 (xx)
CN (1) CN1829917B (xx)
AT (1) ATE403867T1 (xx)
AU (1) AU2004269076B2 (xx)
CA (1) CA2532726C (xx)
DE (1) DE602004015611D1 (xx)
DK (1) DK1649287T3 (xx)
ES (1) ES2310732T3 (xx)
HK (1) HK1094036A1 (xx)
MX (1) MXPA06001382A (xx)
PL (1) PL1649287T3 (xx)
WO (1) WO2005022157A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1931998T3 (pl) 2005-09-15 2010-11-30 Alk Abello As Sposób ilościowego oznaczania alergenów
CA2629923C (en) * 2005-11-24 2014-10-14 Alk-Abello A/S A method of measuring enzymatic activity of adsorbed allergenic enzyme
BRPI0618972A2 (pt) * 2005-11-24 2011-09-20 Alk Abello As Métodos de medição da atividade imunológica e para quantificação da quantidade de enzima alergênica em uma preparação de vacina
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
EP4387594A1 (en) * 2021-08-17 2024-06-26 Innovar Scientific, Inc. Vaccine assessment and compliance testing methods and systems

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
WO2005022157A1 (en) 2005-03-10
CN1829917B (zh) 2010-08-25
KR20060126892A (ko) 2006-12-11
PL1649287T3 (pl) 2009-04-30
CA2532726A1 (en) 2005-03-10
ATE403867T1 (de) 2008-08-15
EP1649287B1 (en) 2008-08-06
ES2310732T3 (es) 2009-01-16
EP1649287A1 (en) 2006-04-26
DK1649287T3 (da) 2008-11-24
AU2004269076B2 (en) 2007-09-20
AU2004269076A1 (en) 2005-03-10
CA2532726C (en) 2013-03-12
DE602004015611D1 (de) 2008-09-18
KR101132439B1 (ko) 2012-03-30
CN1829917A (zh) 2006-09-06
MXPA06001382A (es) 2006-08-25

Similar Documents

Publication Publication Date Title
HK1094036A1 (en) Evaluation of adjuvanted vaccines
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
DE602004031017D1 (de) Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort
ATE188487T1 (de) Anti-gp39 antikoerper und deren verwendungen
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
TR200103333T2 (tr) Dayanıklığı ve biyolojik uygunluğu iyileştiren yardımcı ilaç (SBA)
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
WO2005078450A3 (en) Method for the detection of early b cell populations in vaccine development
WO2004073319A3 (en) Methods and compounds for raising antibodies and for screening antibody repertoires
WO2001079274A8 (en) Tuberculosis antigens and methods of use thereof
Karbach et al. Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
NO986088D0 (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisi
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
AU6008800A (en) Preparation of spheres for diagnostic tests
WO2004032599A3 (en) Novel immunogenic proteins of leptospira
WO1998036089A3 (de) Testkit für tuberkulosediagnose durch bestimmung von alanindehydrogenase
RU2006112203A (ru) Экспресс-тест для диагностирования болезни альцгеймера
Castric et al. Peptide epitope mapping in vaccine development: Introduction

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160728